Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).

[1][2][3] As of 2014, it is in phase II clinical trials for this indication.

[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.

This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.